AuctuCel Expands into South Korea Through Partnership with JCBIO to Advance Biomanufacturing
Strategic partnership marks AuctuCel's expansion beyond Southeast Asia, with an initial focus on supporting South Korea's cell therapy ecosystem
SINGAPORE / SEOUL, South Korea – 30 July 2026 – AuctuCel Pte Ltd, a Singapore biotechnology company specialising in AI-powered bioprocess technologies and advanced cell culture media, today announced a strategic partnership with JCBIO, one of South Korea's leading biotechnology companies.
Through the partnership, JCBIO will distribute AuctuCel's cell therapy culture media in South Korea, strengthening access to high-quality culture media solutions for researchers, biotechnology companies and cell therapy developers. While the partnership will initially focus on cell therapy applications, it also reflects AuctuCel's broader vision of advancing next-generation biomanufacturing through innovative cell culture solutions.
The partnership marks AuctuCel's expansion beyond Southeast Asia into one of the world's leading biotechnology markets. South Korea is internationally recognised for its vibrant biotechnology ecosystem, world-class research institutions and strong leadership in cell therapy and regenerative medicine, making it a strategic market for AuctuCel's continued global growth.
"Our partnership with JCBIO represents an important milestone asAuctuCel expands beyond Southeast Asia into one of the world's leading biotechnology markets," said Dr Chee Wai Fhu , Chief Executive Officer of AuctuCel. "Our current focus is supporting South Korea's growing cell therapy ecosystem, while building long-term collaborations that advance next-generation biomanufacturing through innovative cell culture solutions."
To commemorate the partnership, AuctuCel Co-founder Dr Zach Pang visited JCBIO's headquarters and laboratories in South Korea to meet the team and explore future collaboration opportunities.
"It was inspiring to experience Korea's vibrant biotechnology scene firsthand and witness the collaborative spirit that's accelerating innovation across the industry," said Dr Zach Pang, Co-founder and Chief Scientific Advisor of AuctuCel. "We believe this partnership is just the beginning of stronger scientific collaboration between Singapore and South Korea as we work together to advance biomanufacturing."
The partnership reflects both companies' shared commitment to strengthening scientific collaboration, supporting innovation, and advancing the future of biomanufacturing across Asia.
About AuctuCel
AuctuCel Pte Ltd is a Singapore biotechnology company specialising in AI-powered bioprocess technologies and advanced cell culture media. Founded as an A*STAR spin-off, the company develops customisedand ready-to-use culture media solutions to improve manufacturing performance across cell therapy, biologics and other advanced biomanufacturing applications.
About JCBIO
JCBIO is one of South Korea's leading biotechnology companies, providing products and solutions for life science research, bioprocessing and regenerative medicine. The company works closely with researchers, biotechnology companies and healthcare institutions to accelerate innovation across South Korea's biotechnology sector.
